甘精胰岛素U300与德谷胰岛素U100在1型糖尿病中的药效学头对头比较
本研究为单盲随机交叉试验,纳入22例1型糖尿病患者,经3个月个体化滴定基础胰岛素后,比较甘精胰岛素300 U/mL与德谷胰岛素100 U/mL在稳态下的24小时葡萄糖钳夹药效学。两种胰岛素降糖效果等效,但甘精胰岛素U300的日内药效变异性更低。
要点
- 甘精U300与德谷U100在1型糖尿病稳态下药效学等效。
- 甘精U300的日内药效变异性比德谷U100低23%。
- 甘精U300临床剂量高于德谷U100,但24小时分布相似。
核心结论
- 在1型糖尿病中,个体化临床滴定剂量的甘精U300与德谷U100在稳态下达到相似的血糖控制和药效学等效。
研究设计与样本
- 单盲、随机、交叉研究,纳入22例1型糖尿病患者(11例男性,年龄44.3±12.4岁,病程25.5±11.7年,A1C 7.07±0.63%,BMI 22.5±2.7 kg/m²),进行24小时正常血糖钳夹。
主要发现
- 甘精U300和德谷U100均轻微且相似地降低A1C。
- 钳夹期间24小时平均血浆葡萄糖达正常血糖水平。
- 葡萄糖输注率曲线下面积(AUC-GIR[0-24h])比值为1.04(90% CI 0.91-1.18),表明等效。
- 前12小时甘精U300对内源性葡萄糖生成、游离脂肪酸、甘油和β-羟丁酸的抑制分别比德谷U100强9%、14%、14%和18%。
- 甘精U300的相对日内药效变异性比德谷U100低23%(比值0.77,90% CI 0.63-0.92)。
关键数值与推荐
- 甘精U300剂量为0.34±0.08 U/kg,德谷U100剂量为0.26±0.06 U/kg。
临床怎么用
- 临床滴定甘精U300与德谷U100均可提供相似的1型糖尿病血糖控制。
- 甘精U300可能需要更高剂量,但日内药效更稳定。
局限性
- 样本量较小(N=22),研究周期为3个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To prove equivalence of individual, clinically titrated basal insulin doses of glargine 300 units ⋅ mL-1 (Gla-300) and degludec 100 units ⋅ mL-1 (Deg-100) under steady state conditions in a single-blind, randomized, crossover study, on the glucose pharmacodynamics (PD) in people with type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: Subjects with T1D (N = 22, 11 men, age 44.3 ± 12.4 years, disease duration 25.5 ± 11.7 years, A1C 7.07 ± 0.63% [53.7 ± 6.9 mmol ⋅ mL-1], BMI 22.5 ± 2.7 kg · m-2), naïve to Gla-300 and Deg-100, underwent 24-h euglycemic clamps with individual clinical doses of Gla-300 (0.34 ± 0.08 units ⋅ kg-1) and Deg-100 (0.26 ± 0.06 units ⋅ kg-1), dosing at 2000 h, after 3 months of optimal titration of basal (and bolus) insulin. RESULTS: At the end of 3 months, Gla-300 and Deg-100 reduced slightly and, similarly, A1C versus baseline. Clamp average plasma glucose (0-24 h) was euglycemic with both insulins. The area under curve of glucose infused (AUC-GIR[0-24 h]) was equivalent for the two insulins (ratio 1.04, 90% CI 0.91-1.18). Suppression of endogenous glucose production, free fatty acids, glycerol, and β-hydroxybutyrate was 9%, 14%, 14%, and 18% greater, respectively, with Gla-300 compared with Deg-100 during the first 12 h, while glucagon suppression was no different. Relative within-day PD variability was 23% lower with Gla-300 versus Deg-100 (ratio 0.77, 90% CI 0.63-0.92). CONCLUSIONS: In T1D, individualized, clinically titrated doses of Gla-300 and Deg-100 at steady state result in similar glycemic control and PD equivalence during euglycemic clamps. Clinical doses of Gla-300 compared with Deg-100 are higher and associated with quite similar even 24-h distribution of PD and antilipolytic effects.
引用
- Lucidi P, Candeloro P, Cioli P, et al. Pharmacokinetic and Pharmacodynamic Head-to-Head Comparison of Clinical, Equivalent Doses of Insulin Glargine 300 units · mL-1 and Insulin Degludec 100 units · mL-1 in Type 1 Diabetes. Diabetes Care. 2020. PMID: 33444161. doi:10.2337/dc20-1033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。